Benzinga··PrnewswireAnixa Secures Korean Patent for Breast Cancer Vaccine, Bolstering IP Portfolio
Anixa Biosciences secures patent protection in South Korea for breast cancer vaccine technology, advancing its IP portfolio as Phase 1 trial shows 74% immune response rate.
ANIXintellectual propertyclinical trial